SCHEMBL4152900

SCHEMBL4152900

COc1cc(NC(=O)c2ccnc3[nH]c(-c4ccc(F)cc4)nc23)cc(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.51
TP53 P04637 1/20 0.48
EGLN1 Q9GZT9 1/20 0.47
GSK3A P49840 1/20 0.45
ATF1 P18846 1/20 0.43
NFKB1 P19838 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MET P08581 1/20 0.43
MAPT P10636 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MAPK14 Q16539 1/20 0.42
TSHR P16473 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
STIM1 Q13586 1/20 0.42
ORAI1 Q96D31 1/20 0.42
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152842 0.86 GSK3B (0.52) GSK3BTP53GSK3AMETMAPT
SCHEMBL4154104 0.86 GSK3B (0.56) GSK3BL3MBTL1MEN1KMT2A
SCHEMBL4152144 0.84 GSK3B (0.60) GSK3BTP53METMAPTALDH1A1
SCHEMBL4152806 0.84 GSK3B (0.57) GSK3BMETMAPTL3MBTL1MAPK14
SCHEMBL4161624 0.83 GSK3B (0.52) GSK3BTP53NFKB1METMAPT
SCHEMBL4161516 0.82 GSK3B (0.54) GSK3BTP53ALDH1A1KDM4EMEN1
SCHEMBL4152791 0.82 GSK3B (0.73) GSK3BMETL3MBTL1ALDH1A1GAA
SCHEMBL4162649 0.82 GSK3B (0.58) GSK3BGSK3AMAPTTSHRALDH1A1
SCHEMBL13778221 0.82 GSK3B (0.50) GSK3BGSK3AMAPTL3MBTL1MEN1
SCHEMBL4152192 0.81 BRAF (0.51) GSK3BMAPTTSHRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885TP53 480/4885EGLN1 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.